within Pharmacolibrary.Drugs.G_GenitoUrinarySystemAndSexHormones.G03H_Antiandrogens.G03HA01_Cyproterone;

model Cyproterone
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.88,
    Cl = 3.3333333333333333e-06,
    adminDuration = 600,
    adminMass = 100 / 1000000,
    adminCount = 1,
    Vd = 0.06,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0038333333333333336,
    Tlag = 600,
    Vdp = 0.199,
    k12 = 4.166666666666667e-06,
    k21 = 4.166666666666667e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Cyproterone</td></tr><tr><td>ATC code:</td><td>G03HA01</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>100</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>60</td><td>L</td></tr>
    <tr><td>clearance:</td><td>12</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Cyproterone is a steroidal anti-androgen and progestogen, primarily used to treat androgen-dependent conditions such as prostate cancer, severe hirsutism, and in some cases, as part of hormone therapy for transgender women. It is also used in some countries for the treatment of hypersexuality in men. Its use is more limited today due to safety concerns, including potential for hepatotoxicity.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy male volunteers after single oral administration.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.G.G03HA01 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Cyproterone;
